Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Schott Pharma AG KGaA's Debt-to-Equity or its related term are showing as below:
SHTPY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.1 Max: 0.11
Current: 0.08
During the past 6 years, the highest Debt-to-Equity Ratio of Schott Pharma AG KGaA was 0.11. The lowest was 0.01. And the median was 0.10.
SHTPY's Debt-to-Equity is ranked better than 71.94% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs SHTPY: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Schott Pharma AG KGaA Debt-to-Equity Related Terms
Schott Pharma AG KGaA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (SHTPY) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Schott Pharma AG KGaA and its competitors. Over the past decade, Schott Pharma AG KGaA's Debt-to-Equity has ranged from 0.01 to 0.11. According to the industry distribution chart, Schott Pharma AG KGaA ranks #197 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 28.1%.
Is Schott Pharma AG KGaA's Debt-to-Equity too high?
Schott Pharma AG KGaA's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.11. Based on the distribution chart, Schott Pharma AG KGaA ranks #197 out of 702 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #197 out of 702 companies for Debt-to-Equity. This puts Schott Pharma AG KGaA in the upper half of its industry. The industry median Debt-to-Equity is 0.22. Historically, Schott Pharma AG KGaA's own Debt-to-Equity has ranged from 0.01 to 0.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Debt-to-Equity of 0.00. The stock's GF Value™ is $5.35, compared to a current price of $4.37 — trading 18.3% below its estimated fair value. The current Debt-to-Equity is 0.00. Schott Pharma AG KGaA's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 18.3% below its estimated GF Value™ of $5.35.
Key valuation signals for SHTPY:
Debt-to-Equity: 0.00
GF Value™: $5.35 vs. price of $4.37 (18.3% below fair value)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
69GF Score
Get the complete analysis for SHTPY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
